Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Financing Activities (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Cash from Financing Activities data on record, last reported at $11.6 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 0.53% year-over-year to $11.6 million; the TTM value through Sep 2025 reached $51.7 million, down 6.47%, while the annual FY2024 figure was $56.8 million, 7.63% up from the prior year.
  • Cash from Financing Activities reached $11.6 million in Q3 2025 per NWBO's latest filing, down from $12.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $23.7 million in Q4 2021 and bottomed at $3.9 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $12.4 million, with a median of $11.7 million recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: crashed 63.71% in 2021, then soared 220.97% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $23.7 million in 2021, then crashed by 52.04% to $11.4 million in 2022, then increased by 26.99% to $14.4 million in 2023, then grew by 10.59% to $15.9 million in 2024, then dropped by 27.5% to $11.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $11.6 million in Q3 2025, $12.4 million in Q2 2025, and $11.7 million in Q1 2025.